
Dr. Mahima Rama
Co-Founder, OXY Oral Sciences Pvt Ltd
BDS (Dayananda Sagar Institutions) · MSc Health Services Management (University of Glasgow) · Chartered Manager (CMgr MCMI) · GDC-registered Dental Therapist (UK)
A NEW NIGHT RITUAL IS FORMING
A leave-on mineral ritual designed around the hours your usual toothpaste leaves behind.
OXY
Shield
NOT A TOOTHPASTE DROP
A clinical ritual.
Revealed in layers.
First through accredited clinics in Kochi and Bengaluru. A US + UK interest list is open for the curious, for clinicians and for partners.
THE OVERNIGHT OPPORTUNITY
Most oral-care routines are built around the act of brushing. OXY Shield is built around what happens after it.
Its leave-on format extends contact into the quietest part of the day: after the final brush, before sleep.
See how the ritual worksA DIFFERENT FORMAT
Applied, brushed, then washed away as part of a familiar morning or evening routine.
Applied at night, then left in place. Foam is a sensory cue — not a therapeutic mechanism.
THREE MOVES. ZERO RINSE.
OXY Shield is used differently from a rinse-off paste. The sequence is deliberately simple, so the leave-on format can remain part of the night.

Begin with a dry toothbrush and a small amount of OXY Shield.

Brush gently for two minutes as the formula spreads across the tooth surface.

Spit out the excess, leave the remaining film in place, and head to bed.
Foam is a sensory cue — not a therapeutic mechanism.
EVIDENCE, WITH CONTEXT
Use the control to compare representative FE-SEM views. The result shown is laboratory evidence, not an outcome in people.

>85%
Tubule occlusion in accredited-lab FE-SEM testing (in vitro)
Tubule pathway occluded
IN-VITRO TESTING ON HUMAN DENTIN SPECIMENS (extracted teeth, accredited lab)
An in-vitro FE-SEM tubule-occlusion dossier using acid-etched human dentin specimens at an accredited laboratory.
A CTRI-registered, split-mouth randomised pilot study (n=60) with Schiff and VAS endpoints, plus scheduled ISO 10993 biocompatibility testing.
Outcomes in people. Laboratory images are a starting point, not a promise. We make no claim of benefit in people until human data exists.
FOR THE CURIOUS
What we know, what we are still testing, and what we will not say until the data does.
Saliva flow naturally slows during sleep. Most pastes are rinsed away within minutes of brushing, so the overnight hours go largely untouched. OXY Shield is designed for that window: applied last thing at night and left in place.
The formula is anhydrous — made without water. That is what allows a leave-on format with a dry brush and no rinse, rather than a foam that is spat and washed away.
Laboratory FE-SEM imaging of acid-etched human dentin specimens, tested in vitro at an accredited lab. It is mechanism-level evidence. It is not a clinical outcome, and we present it that way.
A CTRI-registered, split-mouth randomised pilot study (n=60) measuring sensitivity with Schiff and VAS scales, plus ISO 10993 biocompatibility testing.
Not yet. OXY Shield has not been cleared by the FDA or UKCA/MHRA and is not offered for sale outside India. You can join the interest list to hear about the science and any future availability.
Our model is clinic-led: dentists introduce the ritual chairside and patients reorder from them. Kochi and Bengaluru let us build that model with clinics we know, under one regulatory pathway, before anywhere else.
No. OXY is built to work alongside professional care, not around it. If you have pain or sensitivity, see a dentist.
THE PEOPLE BEHIND OXY
Two clinician-operators, trained in India and the UK, building a more considered daily oral-care ritual — and documenting the evidence as it develops.

Co-Founder, OXY Oral Sciences Pvt Ltd
BDS (Dayananda Sagar Institutions) · MSc Health Services Management (University of Glasgow) · Chartered Manager (CMgr MCMI) · GDC-registered Dental Therapist (UK)

Co-Founder, OXY Oral Sciences Pvt Ltd
BDS (Dayananda Sagar Institutions) · MSc Health Services Management (University of Glasgow) · Chartered Manager (CMgr MCMI) · GDC-registered Dental Therapist (UK)
BEYOND KOCHI AND BENGALURU
OXY is not available for sale in the US or UK. But if the idea of an overnight, waterless ritual has you curious, there is a way in — whoever you are.
For people who read ingredient lists and study methods. Plain-language science notes as the evidence develops, and first word if availability changes.
For dentists, hygienists, therapists and distribution partners. A practitioner briefing on the format and evidence, and early conversations about regulated routes to market.
For people evaluating the company. A conversation with the founders about the clinic-led model, the evidence programme and the regulatory roadmap.
FOUNDING CLINIC ECONOMICS · KOCHI + BENGALURU
The Founding 50. 12-month, 1.5 km radius protection, renewable on performance, plus locked founding-tier pricing and co-branded Founding Clinic status.
Indian-market terms only. US and UK terms have not been set — register interest instead.
| Arrangement | Unit | At-a-glance |
|---|---|---|
| Clinic wholesale | ₹720/unit (GST-inclusive) | 20-unit caddy = ₹14,400 |
| Retail MRP | ₹900 (GST-inclusive) | 20-unit retail value = ₹18,000 → ₹3,600 margin (20%) |
| Refill D2C | flat ₹75 onboarding fee per enrolled patient (documented services) | |
| Consignment option | 10-unit starter at ₹7,200, payable on Day 21 against actual sales | |
Counsel-reviewed professional fee structure. No per-prescription commissions. Full opinion available at onboarding.
20% chairside margin (₹720 wholesale / ₹900 MRP). Flat ₹75 patient-onboarding service fee for documented follow-up services — paid for the service, whether or not the patient reorders. Counsel-reviewed, professionally invoiced, disclosed to patients. Non-exclusive.
WHATSAPP-FIRST ENQUIRIES · INDIA
Consent is recorded before WhatsApp opens. OXY does not accept enquiries through an unprotected web inbox. Outside India? Use the US + UK interest list.